Ciprofibrate

Ciprofibrate (Win35833) is a potent peroxisome proliferator and increases the phosphorylation level of the PPARalpha^[1]. Ciprofibrate acts as an orally active hypolipidaemic agent and can be used for the research of primary hyperlipidaemias^[2]. In Vitro: Ciprofibrate (500 μM; 4 hours) increases the PPARa phosphorylation level in rat Fao cells^[1].
In a LucLite assay, Ciprofibrate (10-100μM; 24 hours) induces PPARR activation by existing increased LUC activities in the rat liver H4IIEC3 cells transfected with PPRE-AB LUC reporter gene plasmid^[2].
Ciprofibrate (10-100 μM; 24 hours) is not cytotoxic for HepG2 cells, and the cell viability is 99.7%^[3].
Ciprofibrate (100 μM; 24 hours) also abolishes FFAs mixture-induced lipid deposition and decreases FFAs mixture-increased TG contents?in HepG2 cells^[3].
Ciprofibrate (100 μM; 24 hours) almost entirely eliminates the FFAs mixture-induced inflammatory cytokines overproduction, including MCP-1, TNF-α, and IL-6 in HepG2 cells^[3].
In Vivo: Ciprofibrate (oral administration; 10 mg/kg/day; 3 days) does not result in any significant effects on body weight or absolute liver weight for MCD diet-fed mice. Ciprofibrate improves hepatic steatosis and reduced hepatic necro-inflammation in MCD diet-fed mice. It also reduced hepatic cytokine protein and mRNA levels (MCP-1, TNFα and IL-6) as compared to those of ?choline-deficient (MCD) diet-fed mice^[3].